Isradipine, raised glycosylated haemoglobin, and risk of cardiovascular events

Lancet. 1997 Oct 11;350(9084):1075-6. doi: 10.1016/S0140-6736(05)70455-4.
No abstract available

Publication types

  • Clinical Trial
  • Comparative Study
  • Letter
  • Randomized Controlled Trial

MeSH terms

  • Arteriosclerosis / drug therapy
  • Blood Glucose / metabolism
  • Calcium Channel Blockers / adverse effects*
  • Cardiovascular Diseases / etiology*
  • Carotid Artery Diseases / drug therapy
  • Diuretics
  • Glucose Intolerance / complications*
  • Glycated Hemoglobin / analysis
  • Humans
  • Hydrochlorothiazide / therapeutic use
  • Hypertension / complications
  • Isradipine / adverse effects*
  • Middle Aged
  • Risk Factors
  • Sodium Chloride Symporter Inhibitors / therapeutic use

Substances

  • Blood Glucose
  • Calcium Channel Blockers
  • Diuretics
  • Glycated Hemoglobin A
  • Sodium Chloride Symporter Inhibitors
  • Hydrochlorothiazide
  • Isradipine